Beaumont v. Branch

CourtDistrict Court, D. South Carolina
DecidedAugust 9, 2024
Docket2:23-cv-03546
StatusUnknown

This text of Beaumont v. Branch (Beaumont v. Branch) is published on Counsel Stack Legal Research, covering District Court, D. South Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Beaumont v. Branch, (D.S.C. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF SOUTH CAROLINA CHARLESTON DIVISION

ERIC BEAUMONT, ) ) Plaintiff, ) ) No. 2:23-cv-03546-DCN vs. ) ) ORDER WALTER SCOTTY BRANCH; SHEA C. ) HARRELSON; AVANTE DIAGNOSTICS ) LLC, a Delaware entity; MEDCOAST LLC, ) a South Carolina entity; VIKOR ) SCIENTIFIC LLC, a South Carolina entity; ) BIODXX, INC., a Pennsylvania entity; ) INDEPENDENT CLINICAL ) LABORATORIES, INC., a Florida entity; ) KOR LIFE SCIENCES LLC, a South Carolina ) entity; KORPATH HOLDINGS, LLC, a South ) Carolina entity; and SILVERPATH INC, a ) Pennsylvania entity, ) ) Defendants. ) _______________________________________)

The following matter is before the court on plaintiff Eric Beaumont’s (“Beaumont”) motion to compel discovery responses. ECF No. 36. Specifically, it is before the court on the request for attorney’s fees included in the motion to compel. Id. For the reasons set forth below, the court finds as moot the motion to compel and grants the request to award attorney’s fees related to the motion to compel and awards $28,139.00 in attorney’s fees and $1,588.45 in costs, totaling $29,727.45. I. BACKGROUND This dispute arises from two interrelated agreements to invest funds into start-up laboratory ventures to allow those ventures to expand and roll out “revolutionary laboratory diagnostic testing.”1 ECF No. 42, 2d Amend. Compl. ¶ 15. Defendants Walter Scotty Branch (“Branch”) and Shea C. Harrelson (“Harrelson”) approached Beaumont to solicit funding for their laboratory ventures and promised him “that his investment would make him a partner and co-owner in their laboratory ventures, and, if

they succeeded, he would receive lifelong returns that would provide for his family for the rest of their lives.” Id. ¶ 16. Beaumont entered into the first investment agreement with Branch and Harrelson on August 23, 2017, (the “August 2017 Agreement”) wherein Beaumont agreed to provide $100,000 in exchange for 1.5% of Branch and Harrelson’s laboratory ventures’ gross profits. See ECF No. 42-1. At the time of the August 2017 Agreement, Branch and Harrelson had formed MedCoast LLC (“Medcoast”) which had an existing contract with North Central Florida Neurodiagnostic Services (“NCF”). After the initial investment, Branch and Harrelson grew their laboratory ventures, and on September 13, 2017, they formed Avante Diagnostics LLC (“Avante”). Within days of the first investment, Branch solicited Beaumont for an additional $150,000 in exchange

for fifteen percent of Branch’s own partnership interest in the laboratory ventures, which they formalized through payment and a written agreement fully executed on September 21, 2017 (the “September 2017 Agreement”). See ECF No. 42-2. Together, Beaumont received two types of ownership or profit interests in exchange for his high-risk investments: (1) 1.5% of gross profits from Branch and Harrelson’s laboratory ventures; and (2) fifteen percent of Branch’s partnership interest in those ventures.

1 The court dispenses with citations throughout the background section and clarifies that, unless otherwise identified, the facts come from the second amended complaint. ECF No. 42, 2d Amend. Compl. Starting in the fall of 2017, Beaumont began receiving separate payments pursuant to the two agreements. He initially received payments directly from NCF under the August 2017 Agreement and received payments from Branch personally under the September 2017 Agreement. However, the payments from NCF ceased after about six

months when Branch and Harrelson stopped conducting business with NCF. Id. ¶ 34. Thereafter, starting in March 2018, payments under the August 2017 Agreement came directly from Harrelson. For approximately the first six-to-nine months, Beaumont was able to verify, through an online portal, that the payments he received under the August 2017 Agreement accurately reflected the true percentage of the ventures’ gross profits. Consistent with the laboratories’ growth, Beaumont’s payments under the August 2017 Agreement dramatically increased from an initial payment of $2,162.83 on October 18, 2017, to monthly payments of more than $20,000 in September and October 2018. Around that same time, Branch and Harrelson terminated Beaumont’s access to the online portal, and on May 16, 2018, Branch and Harrelson formed Vikor Scientific LLC

(“Vikor”). On July 23, 2018, Branch and Harrelson formed BioDXX Inc. (“BioDXX”), which initially operated Vikor’s sister laboratory, KorGene, in Pennsylvania. On September 24, 2018, Branch and Harrelson formed Silverpath, Inc. (“Silverpath”), which became the operating entity for the KorGene laboratory.2 After a payment on October 26, 2018, payments ceased for approximately six months during a restructuring and transition period. As of the restructuring, Beaumont had received $225,147.71 from his investments.

2 BioDXX and Silverpath are, together, referred to as “KorGene.” 2d Amend. Compl. ¶ 7. On April 13, 2019, Beaumont provided his bank account information to Harrelson to facilitate anticipated payments coming from Vikor starting on April 15, 2019. On April 17, 2019, Beaumont began receiving payments solely from Vikor, as opposed to from Harrelson or Branch. On May 23, 2019, Branch emailed Beaumont to express that

the Eliminating Kickbacks in Recovery Act of 2018 (“EKRA”), 18 U.S.C. § 220, meant that they could no longer pay per sample or tied to revenues, which restricted Branch and Harrelson’s ability to comply with the August 2017 Agreement and the September 2017 Agreement. As such, Branch and Harrelson limited Beaumont’s payment to $7,500 per month every month moving forward, rather than a percentage of gross profits or ownership as was stipulated by the agreements. Beaumont received $7,500 per month for nearly three years. Beaumont avers that Branch and Harrelson misrepresented the impact of EKRA on the agreements, and in so doing, Harrelson, Branch, and Vikor willfully, wantonly, or at the very least, recklessly “purposefully [and] severely reduc[ed] Mr. Beaumont’s payments.” 2d Amend. Compl. ¶ 58.

On March 17, 2020, Branch and Harrelson formed KOR Life Sciences, LLC (“KOR”) which conducts laboratory research focused on personalized medicine, a key feature of the diagnostic testing technology that Vikor and later KorGene helped bring to market. On June 1, 2020, Branch and Harrelson administratively dissolved Avante. On February 24, 2021, Branch and Harrelson created a holding entity for their laboratory ventures: KorPath Holdings, LLC (“KorPath”). Four months later, in June 2021, they purchased another laboratory, Independent Clinical Laboratories, Inc. (“ICL”), in Tampa, Florida. With each transition—from MedCoast to Avante and from Avante to Vikor and KorGene—neither Branch nor Harrelson gave any indication that the changes, or even the dissolution of Avante, somehow changed Beaumont’s interests. However, on February 15, 2023, Vikor’s Chief Financial Officer Kelly Diamiano (“Diamiano”)

emailed Beaumont to explain that the company was restructuring its ownership and that the email served as a ninety-day notice that his monthly payments of $7,500 would cease. As of the filing of the complaint, Beaumont had received a total of $609,666.71. On April 26, 2023, Beaumont served Vikor, Branch, and Harrelson with a Notice of Breach and Demand for Good-Faith Negotiations, which disputed both the allegedly EKRA- based 2019 unilateral payment modification and defendants’ new unilateral modification terminating Beaumont’s interests and ceasing payments altogether. Defendants responded through counsel, and the parties unsuccessfully attempted mediation. On July 21, 2023, Beaumont filed this lawsuit against defendants pursuant to diversity jurisdiction, 28 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Westmoreland Coal Co. v. Cox
602 F.3d 276 (Fourth Circuit, 2010)
Hickman v. Taylor
329 U.S. 495 (Supreme Court, 1947)
Hensley v. Eckerhart
461 U.S. 424 (Supreme Court, 1983)
Pierce v. Underwood
487 U.S. 552 (Supreme Court, 1988)
Super Duper, Inc. v. Mattel, Inc.
382 F. App'x 308 (Fourth Circuit, 2010)
Fox v. Vice
131 S. Ct. 2205 (Supreme Court, 2011)
Bizprolink, LLC v. America Online, Inc.
140 F. App'x 459 (Fourth Circuit, 2005)
Grissom v. the Mills Corp.
549 F.3d 313 (Fourth Circuit, 2008)
Decision Insights, Inc. v. Sentia Group, Inc.
311 F. App'x 586 (Fourth Circuit, 2009)
Robinson v. Equifax Information Services, LLC
560 F.3d 235 (Fourth Circuit, 2009)
Guidry v. Clare
442 F. Supp. 2d 282 (E.D. Virginia, 2006)
CoStar Group, Inc. v. LoopNet, Inc.
106 F. Supp. 2d 780 (D. Maryland, 2000)
Xiao-Yue Gu v. Hughes STX Corp.
127 F. Supp. 2d 751 (D. Maryland, 2001)
Eileen McAfee v. Christine Boczar
738 F.3d 81 (Fourth Circuit, 2013)
Perdue v. Kenny A. ex rel. Winn
176 L. Ed. 2d 494 (Supreme Court, 2010)
Rum Creek Coal Sales, Inc. v. Caperton
31 F.3d 169 (Fourth Circuit, 1994)

Cite This Page — Counsel Stack

Bluebook (online)
Beaumont v. Branch, Counsel Stack Legal Research, https://law.counselstack.com/opinion/beaumont-v-branch-scd-2024.